179 related articles for article (PubMed ID: 1609193)
21. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Li JM; Giver CR; Waller EK
Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
[TBL] [Abstract][Full Text] [Related]
22. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
Cobbold SP; Hale G; Clark MR; Waldmann H
Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
[TBL] [Abstract][Full Text] [Related]
23. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
[TBL] [Abstract][Full Text] [Related]
24. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
Truitt RL; Atasoylu AA
Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
[TBL] [Abstract][Full Text] [Related]
25. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
26. Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat.
Weijtens M; van Spronsen A; Hagenbeek A; de Weger R; Martens A
Exp Hematol; 2004 Oct; 32(10):962-9. PubMed ID: 15504552
[TBL] [Abstract][Full Text] [Related]
27. Comparison of three techniques for the ex vivo elimination of T cells from human bone marrow.
Blazar BR; Quinones RR; Heinitz KJ; Sevenich EA; Filipovich AH
Exp Hematol; 1985 Feb; 13(2):123-8. PubMed ID: 3882442
[TBL] [Abstract][Full Text] [Related]
28. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
29. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
30. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
32. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
Sykes M; Sharabi Y; Sachs DH
Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
[TBL] [Abstract][Full Text] [Related]
33. Developments in purging in autotransplantation.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1993 Jun; 7(3):687-715. PubMed ID: 8344886
[TBL] [Abstract][Full Text] [Related]
34. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
35. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
Aizawa S; Kamisaku H; Sado T
Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
[TBL] [Abstract][Full Text] [Related]
36. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
37. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
38. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
39. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
[TBL] [Abstract][Full Text] [Related]
40. Prevention of graft-versus-host disease by using immunotoxins.
Laurent G; Bouloux C
Prog Clin Biol Res; 1992; 377():129-36; discussion 137. PubMed ID: 1438408
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
